Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New scams are always great news. New stuff I can expose
HLTT came out with a letter to stock holders in which it said that it sold 776k of it's wound care products in September and an increasing amount every month since in the fourth quarter. The letter is below and also filed with the SEC.
HEALTHTECH SOLUTIONS, INC.
181 Dante Avenue
Tuckahoe, New York 10707
Annual letter to our shareholders and employees
Greetings:
As the new year emerges, I am using this occasion to reflect on the progress made by your company (“HLTT”) during 2022 and the prospects that we see for 2023. We ended 2021 as a medical technology incubator with only a series of scanning technologies, all of which were a distance from potential revenue. We ended 2022 with multiple profit centers already generating substantial revenue or poised to do so.
Our growth during 2022 can be understood as expansion in three integrated vectors: expansion of technology, expansion of skills, expansion of markets. I will summarize our principal accomplishments in each.
Technology: Acquisition of Wound Care IP.
In January 2022, HLTT acquired the assets of a Utah-based biomedical company related to production of wound care treatments. These assets included an FDA licensed manufacturing facility with equipment, intellectual property, including patents, related to wound care, and a skilled management team. The team included the Laboratory Director, the Chief Laboratory Officer, the Senior Vice President of Quality and Regulatory, and the Chief Medical Officer of the manufacturing lab facility.
In the Spring of 2022, we completed the licensing of our initial wound care product line and appointed World Reach Health, LLC (“WRH”), an experienced distributor of biomedical products (more on WRH below), to develop a market for our wound care products. That market produced its first sales in September 2022, and we reported net revenue of $776,221 for that month. We have recorded increased wound care revenue for each month in the fourth quarter of 2022, and we expect wound care revenue to continue to grow during 2023.
Skills: Acquisition of World Reach Health.
Our relationship with World Reach Health grew throughout 2022, as we saw the potential for mutual benefit to HLTT and to WRH from an enhanced relationship. Jelena Olmstead and Jim Pesoli, the owners and principals of WRH, each worked closely with HLTT management to build the HLTT wound care business. They were also instrumental in establishing our new CLIA lab (see below).
In December 2022, the growth of the relationship culminated in the execution of a binding contract under which HLTT will acquire 51% of the membership interest in World Reach Holdings, the parent company of World Reach Health (WRH). The closing will occur in January 2023. WRH is a distributor of biomedical products and medical devices. It sells directly to medical professionals and also has established a nationwide network of sub-distributors.
1
The acquisition will provide HLTT assurance of access to markets for the products and services that its subsidiaries develop. Of equal significance, the acquisition will bring into HLTT management the skills and experience provided by Jelena Olmstead and Jim Pesoli. At the closing of the World Reach Holdings transaction, Jelena will become the CEO and Jim the Senior Vice President of HLTT.
Jelena Olmstead. With over 20 years of experience in distribution of medical products and services, Jelena has familiarity with all continuums of care: Acute, LTC, Home Health, Hospice and Wound Care Clinics. Jelena was intimately involved in developing of annual sales strategies and plans, developing Wound Care processes, establishing best practices, and launching many emerging products into the market, while managing national sales and operations teams. Prior to organizing World Reach Health, Jelena served as Director of Business Development for NuMotion, which specialized in medical devices for mobility needs. Jelena was personally involved in the distribution of more than $1.5 billion worth of goods annually over the course of her career. Prior to joining NuMotion, Jelena was the Business Development Director and Key Account Manager for Invacare and for Joerns, both global healthcare manufacturers and distributors of DME and medical devices. Jelena was involved in a multitude of M&As throughout her career.
Jim Pesoli. Jim’s 15 years of experience as a healthcare-services executive and transactional attorney commenced when he began negotiating international manufacturing and distribution agreements for a variety of commodities and/or intellectual property rights. Later, he founded and eventually sold, Sonic Cleaning Services, which provided housekeeping and laundry services to nursing homes, assisted living facilities and healthcare institutions throughout the Midwest. Throughout his career, Jim has maintained close relationships with the distributors and manufacturers he represented or worked with. Additionally, as an entrepreneur, Jim has raised over $100 million in venture capital for a myriad of enterprises. Within World Reach Health, Jim has been instrumental in identifying and establishing strategic partnerships and brokering long-term purchasing agreements with product suppliers and purchasers around the globe.
WRH has ongoing contracts to distribute a number of products. These include Endurakit, a non-opiate surgical block for which WRH is one of four national distributors. WRH is the exclusive distributor for MY GEL, which is a neuropathy pain gel. WRH is also an approved distributor for some of the leading COVID-19 diagnostic tests, along with other diagnostic products, which are manufactured by AccessBio and Phase Scientific. WRH is a distributor of the Postday One-Step emergency contraceptive, and WRH is also an authorized distributor of Better Air, which provides organic probiotic air purification solutions. In this fashion, we expect WRH to provide a gateway to market for the products developed by HLTT subsidiaries as well as a source of additions to HLTT’s product list.
2
Markets: Organization of The Clia Lab.
Our current business plan points towards integration of complementary product and service lines, with the goal of maximizing the potential market for products and services developed by our subsidiaries. For example, WRH is well-established as a distributor in the rapid-testing market, which includes testing for Flu, Covid and Mersa. To optimize the opportunities presented by WRH’s presence in that market, the logical next step was to organize our own lab.
In the second half of 2022, therefore, we established an FDA-licensed CLIA laboratory, appropriately named “The CLIA Lab.” This facility is housed at the University of Utah technology campus in Salt Lake City.
The CLIA Lab is licensed to perform the Flu, Covid and Mersa tests that WRH has to date sold for other labs. It is also licensed to perform bacteria testing, providing a new revenue stream for WRH as well as a market advantage for HLTT’s wound care products. We expect to offer bundle packages to our wound care providers, which will include both the clinical test required prior to a wound care treatment as well as the wound care allograft that HLTT manufactures.
The View Forward
The acquisition of WRH later this month will provide HLTT a soup-to-nuts integration of the facilities required to develop biotechnical products and bring them to market. The only external input necessary for significant growth will be funding. Towards that end, management is in discussions with several broker-dealers with a view toward one or more of them sponsoring the uplist of HLTT’s shares to the NYSE American or NASDAQ. We plan to initiate the uplist process, soon after we file our 10-K Annual Report for 2022.
In sum, management expects 2023 to be HLTT‘s breakout year. We thank you for the support and dedication you have shown the company since 2020. We pledge to work tirelessly to assure that your confidence will be well rewarded.
Sincerely,
Manuel E Iglesias, President
Healthtech Solutions, Inc.
January 6, 2023
Thank you for your post
HLTT, pred's partner in wound care, posted its 10Q last month. 776k sales of pred's allograft in September. Looks good.
"Sales of our wound care allografts commenced in September 2022, as we delivered allografts to five customers for an aggregate purchase price, net of discounts, of $776,221. Payments for the sales did not commence until October, so we recorded accounts receivable from the sales of $720,777, representing the net sales revenue less an allowance for doubtful accounts of $55,444. After recording $51,834 in cost of goods sold (i.e. proportionate allocation to the products sold of the direct costs attributable to their production), we recorded gross profit of $720,175 for the three and nine months ended September 30, 2022. We expect that in future periods our gross margin ratio will be lower than the ratio we recorded in the periods ended September 30, 2022."
https://www.otcmarkets.com/filing/html?id=16221949&guid=xrG-kWHM7TC6dth
" Pred will trade again in my opinion." That is not an opinion, it is HOPE !!!!!!
IB_
You are comparing apples to oranges. Pred will trade again in my opinion. As a shareholder, though, I’m definitely not happy right now.
No. Not that platform.
Yes they should but being such a low profile company, they will never face any consequences !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
IB_
BRAD and the GANG should of got the same I mean more.
https://finance.yahoo.com/news/elizabeth-holmes-theranos-founder-sentenced-to-1125-years-in-prison-222816236.html
Have you managed to buy on this platform ?
Some brokerages choose to show B/A.
IBKR app is one of them.
Where do you see quotes?
I know on Think or swim they have the last quotes up from before they went dark, and they never change.
Yes it is quoted. Somehow must have got its 211 back from the suspension.
Are you asking because there has been some consistent trading, if low price and volume? I didn't think there was a 211, but I tried to place a buy order just in case. No luck. There must be some way to buy this stock because people are, but not through any broker I have.
Sometimes life isn’t fair and the world is cold. I am always a believe in Karma when you do people wrong.
What BS ?????????????????????????????????????
The scam is finished,
IB_
How are the people who came on here and Schilled for it able to sleep at night? Hell will await them. Have fun boys.
Orrin Hatch will be remembered for this and it will be his lasting legacy. He probably was senile and was taken advantage of by management.
Great retort. Nothing I said is untrue. Pred is a scam. They royally f'd retail shareholders with help from paid schills and a bullshit board of directors. None of their products are worth a damn. They sold the last remaining product, with zero public insight into how that money was spent.
My best guess is, assuming they actually still have an office, it's probably just Brad and Dr ward running around playing laser tag all day.
Pred sucks. So do their insiders and paid schills.
And we're not trading because pred is a scam company with no money, no revenue, no product, no prospects, no sense of obligation to long term shareholders who have been brutally scammed out of their money by con artist frauds with help from paid schills who pretend to be shareholders.
The lot of whom should be in jail for fraud.
Anyone with their "thinking cap on" can see what this was, a very well orchastrated con by long time con artists. And that there is no hope here. The game is over, shareholders lost, Company leadership, insiders, and schills won by robbing retail investors blind. Truly a great con, but it was a con.
Gotta love how these non-shareholders are coming in here and fishing for info.
Yup, they still read and post.
Put your thinking cap on. There’s no need to be posting right now because we are not trading at the present time. Duh!!!!
PRED
Wow this board is still active huh? More than you can say about predictive lol
Does pred even still maintain an office/lab space?
Remember when everyone said this dream team was going to be worth billions? And then their cutting edge tests turned out to be total bs? Good times.
Wonder why the big guy hasn't posted any updates recently.
What a crock scam this one turned out to be, curious how much the "board members" got paid to attach their names to the company? They should all be in jail.
It was a head fake, Tree shaking, look at the rally just getting started !!!!!!!!!!!!!!!!!!!
LoL LoL,
IB_
Wow Pred is 70% off today ? Is there a celebration in here?
Oh my, PRED is being pulled down by the Fed !!!!!!!!!!!!!!!!!!!!!!!
IB_
Brian feel bad for those that got stuck herein pred ..whether it was a scam or bad luck or bad biz decisions is irrelevant at this point. Are you still looking for a miracle with the elgl /bfnh crowd ...the amount of hopium being sold from that group still is amazing. I only got saved because i said i wouldnt hold or buy until i saw insider open mkt buys down there in the pennys when someone like JS wasnt buying at those prices neither did I ..good luck hope you recoup somehow.
Well kind zhangguangming we can agree to disagree on that statement you said. Almost like you saying UCLA is just like USC.
Not a good guy, a GREAT guy!
looks like ryan cohen pulled a brad and bagged everyone in BBBY..looks alot like what happened with Pred.
Hope so !!
Under Rule 12g-1, the JOBS Act and the FAST Act, the thresholds for registration and termination of registration for a class of equity securities under Exchange Act Section 12(g) were raised. As a result of the statutory changes, an issuer that is not a bank, bank holding company or savings and loan holding company is required to register a class of equity securities under the Exchange Act if:
a. it has more than $10 million of total assets; and
b. the securities are “held of record” by either 2,000 persons, or 500 persons who are not accredited investors.
The JOBS Act also directed the Commission to revise the definition of “held of record” to exclude securities held by persons who received the securities under an “employee compensation plan” in transactions exempted from the registration requirements of Section 5 of the Securities Act of 1933 and to create a safe harbor that issuers can follow when making that determination.
This means he is claiming to have less than $10M in assets and he has less than 500 shareholders out there. This is a self-certification. I am “sure” it is accurate.
Can't possibly be 500 or more people out there holding shares or he would have committed securities fraud ... and what happened to all those assets that valued over $50M as late as June last year. Goodwill, intellectual property? I am sure that the accounting firm would have done everything to avoid a false assessment on how they were valued.
Time to pierce the corporate veil ....
This note is to inform you that a filing has been completed for PREDICTIVE TECHNOLOGY GROUP, INC.. The filing completed was: Annual List of Officers and Directors.
https://esos.nv.gov/EntitySearch/BusinessInformation
yea its done. PRED flushed away like sewage
The Bird Man clearly told me on a phone call, PRED was working on a cure for cancer !!!!!!!!!!!!!
They may be tweaking it for launch soon,
IB_
i was right....
imagine if PRED vestors would have listened to Hindenburg and myself. Woulda saved a lot of money! Crazy how in a mania the past couple years where every single person banked, PRED vestors lost they a** as Joe Biden would say. oh man...
Seriously. The only thing elgl has going for it over pred is it hasnt been suspended yet. (to the best of my knowledge anyway, I haven't followed that pos in a year or two now)
What will pred holders get out of it? There shares bought back at the current market value? 1,000 to 1 pred to elgl shares? It's all bs hype. Typical pink sheet scam bs.
There's a new scam brewing where pred might get folded into elgl. I haven't kept up with the details on the different theories but it's a near certainty that it's meaningless to pred bag holders.
its done. fat lady sang finally. no more hong kong. no more utah china town taco bell pics. no more jerry kramer, thomas etc. the pain is over. PRED is finally finished for good. shoulda listened to me! make sure to check out the podcast on PRED
price target for PRED is .000000000000001 if lucky.
Quote: "New beginnings for Pred" ????????????????????
What is new at PRED ??????????????????????
IB_
Just a little boy who tried to get attention on this board, who talked about his chicken ranch, his whores, skidrow, and other useless nonsense. Oh, and tried to peddle his podcast. Oh, and tried to brag how short he was on the stock. None of which have nothing to do whatsoever with Pred. Just a waste of board space. New beginnings for Pred and hopefully most of these predators will be gone going forward.
Thanks. I could have been classier, but the stubborn baggies that refused to believe anything were very nasty to me. I tried and tried every which way to show the truth in all ways humanly possible, but the bag holders did not listen. i have to say though that you kept it classy. stubborn and blind to the truth as you can see now, but classy.
Once a company is a non reporting company, can a company stay in business and never report financials again?
Followers
|
236
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
54907
|
Created
|
01/02/08
|
Type
|
Free
|
Moderators |
About:
Predictive Technology Group, Inc., a Salt Lake City, UT therapeutics and life sciences company, is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics. Through its’ wholly-owned subsidiaries, Predictive Therapeutics and Predictive Biotech, the company focuses on four main clinical categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products. In addition to Predictive Biotech’s efforts to advance regenerative medicine, Predictive Therapeutics is committed to assisting women in overcoming the devastating consequences of endometriosis via appropriate early-stage diagnosis and subsequent treatment.
• Proven management team with success from R&D, to operations and commercialization
• First product line - internally developed Human Cell and Tissue Products - launched in 2017
• Launched 2 novel, genetic-based endometriosis and fertility diagnostic/prognostic tests in Dec. 2018
• Broad, follow-on pipeline of diagnostics and therapeutics in the near-, mid-, and longterm
• Cash positive operating position with no debt (only operating payables)
• Pursuing a near-term NASDAQ listing
For more information visit: http://predtechgroup.com/
Subsidiaries:
|
|
Investor Resources:
- SEC Filings - EDGAR
- https://predtechgroup.com/wp-content/uploads/2020/02/Predictive_Technology_Group_January_2020_Print.pdf
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |